Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 10:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 215 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Testim Clear all
Completed Phase 4 Interventional

Xiaflex® Plus Testosterone Treatment Pilot Study Protocol

NCT03815331
View directory record Official record
Conditions
Peyronie's Disease (PD)
Interventions
Xiaflex®, Aveed
Drug
Lead sponsor
Men's Health Boston
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 31, 2020 · Synced Oct 27, 2026, 10:38 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic (PK) Study to Compare the Absorption of Two Formulations of Transdermal Testosterone Spray and Intrinsa®

NCT01096329
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Testosterone Spray 5% and 1%, Intrinsa® Patch and Testosterone Spray 5%, Intrinsa® Patch and Testosterone Spray 1%
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 27, 2026, 10:38 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer

NCT05081193
View directory record Official record
Conditions
Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Interventions
Testosterone Undecanoate, Enzalutamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 27, 2026, 10:38 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

The Effect of 5-Alpha Reductase on Testosterone in Men

NCT00070733
View directory record Official record
Conditions
Sex Disorders
Interventions
testosterone enanthate, duastride
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
21 Years to 40 Years · Male only
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2005 · Synced Oct 27, 2026, 10:38 PM EDT
Withdrawn Phase 4 Interventional

Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis

NCT04601233
View directory record Official record
Conditions
Multiple Sclerosis, Erectile Dysfunction, Testosterone Deficiency
Interventions
XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector
Drug
Lead sponsor
Tulane University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 27, 2026, 10:38 PM EDT
Terminated Early Phase 1 Interventional Results available

Testosterone for Penile Rehabilitation After Radical Prostatectomy

NCT00848497
View directory record Official record
Conditions
Hypogonadism, Erectile Dysfunction
Interventions
Testim®, Placebo Testim®, Viagra®
Drug · Other
Lead sponsor
Mohit Khera
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2015 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Phase 2 Interventional Results available

COMbination of Bipolar Androgen Therapy and Nivolumab

NCT03554317
View directory record Official record
Conditions
Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer
Interventions
Testosterone cypionate, Nivolumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
San Francisco, California • Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Phase 1 Interventional

Feasibility Study of Post-hospitalization Interventions to Improve Physical Function in Older Adults

NCT02203656
View directory record Official record
Conditions
Aging
Interventions
Placebo, Nutritional Supplement, In-home exercise, Testosterone
Drug · Dietary Supplement · Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
65 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Oct 27, 2026, 10:38 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Natesto Testosterone Nasal Gel for Hypogonadal Men

NCT05484167
View directory record Official record
Conditions
Erectile Dysfunction, Sexual Dysfunction
Interventions
Natesto Nasal Product, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 64 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Phase 2 Interventional Results available

The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone)

NCT01386606
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal (enclomiphene citrate), Testosterone
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Androgel in the Treatment of Hypogonadal and Low Testosterone Men With Type 2 Diabetes

NCT00141492
View directory record Official record
Conditions
Type 2 Diabetes, Hypogonadism
Interventions
Androgel (testosterone gel)
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
30 Years to 80 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
70
States / cities
Birmingham, Alabama • Calera, Alabama • Mobile, Alabama + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2015 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Hormonal Mechanisms of Sleep Restriction

NCT02256865
View directory record Official record
Conditions
Insulin Resistance
Interventions
Ketoconazole, Hydrocortisone, Testosterone, Placebo for ketoconazole, Placebo for hydrocortisone, Placebo for testosterone
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
22 Years to 45 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2023
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Phase 2 Interventional Results available

Bipolar Androgen-based Therapy for Prostate Cancer (BAT)

NCT01750398
View directory record Official record
Conditions
Recurrent Prostate Cancer
Interventions
Testosterone cypionate, Goserelin, Leuprolide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Phase 2 Interventional

A Study of Megestrol Acetate Alone or in Combination With Testosterone Enanthate Drug in the Treatment of HIV-Associated Weight Loss

NCT00001079
View directory record Official record
Conditions
HIV Infections, HIV Wasting Syndrome
Interventions
Testosterone enanthate, Megestrol acetate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
21
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 27, 2026, 10:38 PM EDT
Recruiting Phase 2 Interventional

Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

NCT06039371
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Scan, Carboplatin, Computed Tomography, Etoposide, Quality-of-Life Assessment, Questionnaire Administration, Testosterone Cypionate, Radioconjugate, Dual X-ray Absorptiometry, Gallium Ga 68-PSMA-617, Positron Emission Tomography, Single Photon Emission Computed Tomography
Procedure · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Testosterone Replacement Therapy in Chronic Spinal Cord Injury

NCT00266864
View directory record Official record
Conditions
Spinal Cord Injury, Hypogonadism
Interventions
Testosterone Transdermal System (Androderm 5 mg patch)
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 49 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
2
States / cities
West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2017 · Synced Oct 27, 2026, 10:38 PM EDT
Withdrawn Phase 2 Interventional

Testosterone for Fatigue in Men With MS

NCT03000127
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
AndroGel 1 % Topical Gel, Placebos
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Los Angeles, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 6, 2019 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations

NCT00857454
View directory record Official record
Conditions
Hypogonadism
Interventions
Testosterone MD-Lotion
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
11
States / cities
Birmingham, Alabama • Tuscon, Arizona • Burbank, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2011 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Phase 3 Interventional Results available

Time to Eugonadal Range, Time to Steady State and Drying Time

NCT01228071
View directory record Official record
Conditions
Male Hypogonadism
Interventions
testosterone gel 2%
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
Tucson, Arizona • Middlebury, Connecticut • Oviedo, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Phase 3 Interventional Results available

The Cardiac Benefit of Testosterone Replacement in Men With Low Testosterone Levels With Coronary Artery Disease After Successful Intervention of the Blockage or Narrowed Heart Artery

NCT00413244
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
AndroGel 5 Grams, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
40 Years to 75 Years · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Role of 5-alpha Reductase in Mediating Testosterone Actions

NCT00493987
View directory record Official record
Conditions
Healthy
Interventions
Testosterone Enanthate, Dutasteride
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 50 Years · Male only
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2010 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Phase 1 Interventional Results available

Testosterone for Treating Cachexia in Patients With Squamous Cell Carcinoma

NCT00878995
View directory record Official record
Conditions
Cachexia, Squamous Cell Carcinoma
Interventions
Placebo Testosterone, Testosterone Enanthate 100 MG/ML
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Anabolic and Inflammatory Responses to Short-Term Testosterone Administration in Older Men

NCT00957801
View directory record Official record
Conditions
Sarcopenia
Interventions
Testosterone injection, Testosterone gel, Medrol
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
60 Years to 85 Years · Male only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Phase 2 Interventional Results available

The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate

NCT02921386
View directory record Official record
Conditions
Hypogonadism
Interventions
Oral Testosterone Undecanoate
Drug
Lead sponsor
Clarus Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Torrance, California • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 27, 2026, 10:38 PM EDT